FDA Drug Shortage: Sterile Water Irrigant (Current)

FDA Drug Shortage: Sterile Water Irrigant (Current)

Lead

The FDA has designated Sterile Water for Irrigation as a drug in current shortage as of its most recent update to the Drug Shortages Database. The shortage stems from discontinuation of manufacture by the producing entity. Wholesale drug distributors and 3PLs handling sterile injectable products should review their inventory allocation protocols and customer communication procedures for this product category.

Background

Under Section 506E of the Federal Food, Drug, and Cosmetic Act (FD&C Act), enacted through the FDA Safety and Innovation Act of 2012, the FDA maintains a public Drug Shortages Database tracking medically necessary drugs in shortage. Manufacturers are required to notify FDA at least six months in advance of a permanent discontinuation or interruption in manufacturing that is likely to lead to a meaningful disruption in supply. The agency classifies shortages as "current," "resolved," or "discontinued" based on manufacturer reporting and market supply assessments.

Sterile Water for Irrigation is a large-volume sterile irrigation solution used in surgical and wound care settings. It is classified as a sterile drug product under 21 CFR Part 200 and must be manufactured under current good manufacturing practice (cGMP) requirements established in 21 CFR Parts 210 and 211. Unlike Sterile Water for Injection (which is administered parenterally), Sterile Water for Irrigation is not intended for intravenous use, but its sterility requirements remain stringent given its application to exposed tissue during medical procedures.

Key Details

According to the FDA Drug Shortages Database entry, the shortage reason is listed as "Discontinuation of the manufacture of the drug." The database does not specify which manufacturer discontinued production or whether multiple products under different NDC codes are affected. The designation "current" indicates the shortage is ongoing as of the database's last update.

The FDA has not issued a formal shortage alert or revised guidance specific to this product. The entry appears in the standard Drug Shortages Database, which is updated as manufacturers submit discontinuation notices under 21 USC 356c. No therapeutic alternative recommendations or import allocation procedures have been published by FDA for this specific shortage.

Wholesale distributors holding existing inventory of Sterile Water for Irrigation products are not subject to specific FDA allocation requirements at this time. However, entities with state wholesale drug distributor licenses may be subject to state-level shortage reporting or allocation requirements depending on jurisdiction. For example, California Health and Safety Code Section 4164 requires wholesale distributors to report certain drug shortages to the California State Board of Pharmacy.

Impact Assessment

Wholesale drug distributors and 3PLs should assess their current inventory positions for Sterile Water for Irrigation products. Entities serving hospital systems, ambulatory surgical centers, or wound care clinics may experience increased order volume as downstream customers seek to secure supply ahead of broader market recognition of the shortage.

Distributors should verify whether their trading partners have business continuity plans for sterile irrigation product shortages. Under DSCSA transaction information requirements (21 USC 360eee-1(b)(1)(A)), any change in product sourcing or addition of new trading partners to fulfill shortage-driven demand must be accompanied by compliant transaction documentation, including transaction information (TI), transaction history (TH), and transaction statement (TS).

3PLs providing temperature-controlled storage for hospital or surgical customers should confirm that any alternative sterile irrigation products substituted by their customers maintain compatible storage requirements. Sterile Water for Irrigation is typically stored at controlled room temperature (20-25°C), but alternative formulations may have different specifications.

State boards of pharmacy in certain jurisdictions require wholesale distributors to notify the board when a distributor cannot fill an order for a drug in shortage due to insufficient supply. Distributors operating in multiple states should cross-reference state-specific shortage notification requirements against their customer base for this product category.

What ColdChainCheck Data Shows

As of the current database snapshot, ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these entities, 1,234 hold active FDA establishment registrations — the foundational requirement for entities handling sterile drug products. The average compliance score across the directory is 51/100, placing the majority of tracked entities in the "Fair" tier (919 entities). Only 63 entities hold NABP accreditation, representing approximately 5% of the directory.

For entities involved in sterile irrigation product distribution, FDA registration status is non-negotiable. The 41 entities in ColdChainCheck's directory without confirmed FDA registration should not be considered for sourcing sterile products, regardless of state licensure status. Under 21 USC 360(b), every entity engaged in the manufacture, repackaging, relabeling, or salvaging of drug products must register with FDA and list the drugs it handles.

The compliance score distribution indicates that fewer than 2% of tracked entities achieve "Excellent" tier (28 entities) — defined as entities with comprehensive license coverage, active accreditation, and no enforcement actions on record. QA managers evaluating alternative suppliers during a shortage should prioritize entities in the "Good" (281 entities) or "Excellent" tiers, particularly those with NABP accreditation and multi-state licensure.

Practical Guidance for Compliance Officers

• Verify FDA registration status: Use the ColdChainCheck directory to confirm that any new or backup supplier holds active FDA establishment registration. Filter by "FDA Registration: Active" to narrow the list to 1,234 compliant entities.
• Cross-reference state licenses: If your facility operates in a state with specific sterile product handling requirements (e.g., California's additional registration for sterile compounding facilities), confirm the distributor holds the appropriate state-level license. ColdChainCheck displays state-by-state license status for each entity.
• Check enforcement history: Entities with FDA warning letters or recalls related to sterile product handling pose elevated risk during shortage conditions. ColdChainCheck tracks 73 entities with recalls on record — review the enforcement details before onboarding a new supplier.
• Monitor NABP accreditation: While only 63 entities in the directory hold NABP accreditation, this subset represents distributors with third-party verification of compliance with NABP Model Rules. During a shortage, accredited entities may be better positioned to handle increased volume without compliance lapses.

ColdChainCheck tracks FDA drug shortage designations as part of its ongoing regulatory monitoring. For related guidance on wholesale distributor due diligence requirements, see the compliance guides section.

Disclaimer: This content is provided for informational purposes only and does not constitute legal or regulatory advice. Entities should verify all regulatory requirements with the FDA, state boards of pharmacy, and qualified legal counsel before making sourcing or operational decisions.